Cubist Pharmaceuticals Inc

Cubist Pharmaceuticals — FY2004 Earnings Presentation

26 slides from Cubist Pharmaceuticals's earnings presentation, Jan 18, 2005

  1. Slide 1: Serious Infections. Serious Business.

    Serious | Infections. / howe pened or soppee arts pit regan. facxard he aw vacranetnth erp

  2. Slide 2: 2004 Net Product Revenues (Unaudited)

    2004 Net Product Revenues (Unaudited) Q4 2004 $ 21.0 million Full-year 2004 $ 58.6 million

  3. Slide 3: The Case for Cubist

    The Case for Cubist + Large growing unmet medical need + Vancomycin is not the drug it was once thought to be! + Cubicin® approved by FDA » For cSSSt Staphylococcus aureus and other organisms » Significant commercial opportunity » Bacteremia / Endocarditis Phase 3 to drive label expansion + Successf

  4. Slide 4: Increases in U.S. MRSA Rates

    Increases in U.S. MRSA Rates cube Propotin ofS. aureus Nosocomial ifections Resistant to Oxacilin (MRSA) Among ICU Patients 60 50 40 20 —*icu = Non Ieu % Resistant Isolates 2 s 1989 1991 1993 1995 1997 1999 2001 2003 Year “Sources: NNIS (CDC) System, data for 2003 are incomplete

  5. Slide 5: Community MRSA is a Growing Concern

    Community MRSA is a Growing Concern CUBIST Résbs-courter Student dies after lengthy illness Tues Janay $2005 ‘ors Hite Shoo foals tar Bat ded Heya Vande Hopphldur bang. eae teen Co (Opens td cts et fof phy. May sade peing Faure wad fee The Aesociated Pres threat to public health Ne degree intheir pr

  6. Slide 6: U.S. Gram-positive Agents

    i U.S. Gram-positive Agents Growth of Vancomycin, Synercid & Zyvox Units (000) 48,000 , Annual Vancomycin . Growth 1999 ~ 2003: 14.6% 16,000 14,000 12,000 10,000 8,000 6,000 4,000 2,000 17,228 1999 2000 2001 2002 2003 fm Vancomycin IV m Synercid B Zyvox Total Source: IMS Health retail and non-retail

  7. Slide 7: Significant Infections in U.S. Hospitals

    Significant Infections in U.S. Hospitals cube ‘US Hospital All Courses Anti Staph” | Vancomycin | % of Vane Infections’ 2003 2003 2003 Use ‘Skin/Skin Structure 6,963,868 2,392,782 680,976 24% ‘Systemic Infections: 5,408,820 1,131,329 776,805 28% Cardiovascular 335,498 91,325 36,906 1% Gentournary ea

  8. Slide 8: Rising Clinical Failure Rates

    ——— CUBIST Rising Clinical Failure Rates : Relationship of MIC and Bactericidal Activity y Vancomycin for T ct ci ‘Staphylococcus aureus Bacteremia Gong Sats! Fal A. Mo Broder? erm Senne Alan Frit? Wott Mostar sa George NE ete Hay dn Si Pas Se nr oo Fok ls, el sara eaS al Stan Ret ead tt Sct aston T

  9. Slide 9: Quarterly Net Product Revenues

    Dollars in millions - Quarterly Net Product Revenues [Riiny 2004 Net Product Revenues Were $58.6 million (Unaudited) : $2: $2 21.0 $1 18.0 $1 13.2 $5) 63 $ 1004 2004 3Q04 404

  10. Slide 10: Comparison of IV Antibiotic Launches

    Comparison of IV Antibiotic Launches cube ‘Cumulative Sates ($000) $45,000 ‘Cumulative Gross Sales Since Launch (ICS for Cubicin; IMS Non-Retail for others) ——— eg aS rar Sid Recap TT

  11. Slide 11: Cubicin Repeat Accounts

    Cubicin® Repeat Accounts | + Vial orders continue to trend upward — 120 to 130 repeat accounts ordering — 6108 new accounts ordering per day PLPOEGFEEEEEEBLEEEEEDEES ~2-Repeat Customers —Linear (Repeat Customers)

  12. Slide 12: Daily Cubicin Net Product Sales

    Dollars in thousands, rare ‘24 aTD (Unaudited) i Daily Cubicin® Net Product Sales [yey Per Shipping Day ™

  13. Slide 13: CUBICIN Outcomes Registry and Experience

    CORE CUBIST CUBICIN Outcomes Registry and Experience “ + 870 cases, representing 37 sites entered in registry in 2004 — Exceeded goal of registering 700 cases in 2004 + Analysis underway of cSSSI cases in the first extract of data (581 cases) + Datato be presented at scientific meetings and submitte

  14. Slide 14: cSSSI Interim Findings

    CORE CUBIST cSSSI Interim Findings " or 187% fo 198% Wet Macatee Spats Ue ‘Selected pathogens in complicated skin infections (N*122) ea3t 238 fea —T 38 10%, 25% Mk Sst Efmets Signs Sapte ‘om ' Over 70% of e$SSI patients n CORE on CUBICN had rected previous antboctea therapy Pathogens were isolated p

  15. Slide 15: Cubicin Commercialization

    Cubicin® Commercialization cuBIST U.S. Hospital Acute Care Marketing Plan - Marketing Targets A Sales Focus 300 Hospitals B 80% of i ~600 Vancomycin Sales Fm Hospitals D 6400 + Hospitals & OP Ctrs 75 Clinical Business Managers (CBs) in 2005 24 adiltional CBMs; ‘7 Regional Business Directors (RBDs);

  16. Slide 16: Penetration and Formulary Approvals

    Penetration and Formulary Approvals by Type of Account Account Potential Customers % of Potential % Formulary Type | Customers | Ordering | Customers Approval (12781104) Ordering (12113104) (1281104) A 315 280 92% 85% B 562 456 81% 52% c ‘B47 451 53% Not Tracked DIO 7,286 1,843 25% Not Tracked Total

  17. Slide 17: Outpatient Use

    Outpatient Use cube + 38% of total through Q4 2004 + Both “step down” as well as first line therapy + Same physicians as driving inpatient + Ease of use: = Once-daily dosing — Limited or no monitoring — 30 minute infusion time

  18. Slide 18: Launch Summary To Date

    - Launch Summary To Date CUBIST Product Launched November 3, 2003 - + Around 3,040 cumulative unique customers had ordered CUBICIN by end of Q404 Formulary acceptance rate still above expectations — 92% of A and 81% of B accounts had ordered vials of CUBICIN by the end of 4Q04 — 65% of A and 52% of

  19. Slide 19: Endocarditis/Bacteremia Update

    Endocarditis/Bacteremia Update cube + Enrollment in Phase 3 endocarditis/bacteremia trial complete — Results of meeting with the FDA announced 11-9: » Further enrollment of left-sided patients not required » Data from this study, if positive, would support expansion of label to right-sided endocardi

  20. Slide 20: Cubicin International Commercialization

    Cubicin® International Commercialization [UOEu + Chiron Partnership = CUBICIN marketing rights in Western and Eastern Europe, Australia, New Zealand, India, and certain Central American, South American and Middle Eastern Countries = $50 million in upfront and potential milestones to Cubist — Above i

  21. Slide 21: Pipeline

    Pipeline sere Strategic Focus estentens Serious and Life-Threatening Infections Discovery Research r novel

  22. Slide 22: Novel Monoclonal Antibody Product

    CUBIST a, Novel Monoclonal Antibody Product + Licensed from XTL Biopharmaceuticals in June 2004 + Currently in second of two Phase 2 trials for prevention of re-infection by hepatitis B (HBV) in liver transplant patients + Potential advantages over current standard of care — Lower infusion volume/hi

  23. Slide 23: 2nd Generation Lipopeptide Research

    Log (CFUml) canesanor8 0d ons Research cusist 2" Generation Lipopeptide: daptomycin + lung activity Efficacy vs. S. pneumoniae Lung Infection in Mice 1 1.1 log reduction L 5.1 log reduction : 10 mg/kg 100 mg/kg 100 masky Saline ‘Daptomycin Analog X + analog X shows 4 log (99.99%) improvement over da

  24. Slide 24: Natural Products Discovery

    —— Research CUBIST Natural Products Discovery + Novelty > 50% + Screening Assay: 3 log improvement in specificity + New actives and hits under evaluation + Seeking IND Candidates for Development in Near-Term

  25. Slide 25: Selected Balance Sheet Items

    Selected Balance Sheet Items CUBIST (millions) September 30, December 31 2004 2004 (1) Cash and Investments $6 $12 Debt, Capital Lease 196 165 Obligations Shares Outstanding 402 497 (1) unaudited

  26. Slide 26: Searchable text section of graphics shown above

    Searchable text section of graphics shown above Ser ious Infections. [GRAPHIC] [LOGO] Serious Business. Statements made during this presentation that are not historical fact may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important fa

Cubist Pharmaceuticals — FY2004 Earnings Presentation on 6ix